Verastem, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Daniel W. Paterson
- Full Time Employees
- 102
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 117 Kendrick Street Needham MA United States 02494
- IPO Date
- Jan 27, 2012
- CIK
- 0001526119
- Website
- verastem.com
- Similar Companies
- Business
- Verastem, Inc. Verastem, Inc. (VSTM) is a late-stage biopharmaceutical company focused on developing and commercializing novel small molecule drugs targeting the RAS/MAPK signaling pathway in cancer, including RAF/MEK inhibition via avutometinib, FAK inhibition via defactinib, and KRAS G12D inhibition via VS-7375; the company advances these assets in monotherapy and combinations for low-grade serous ovarian cancer (LGSOC), pancreatic cancer, non-small cell lung cancer, colorectal cancer, and other RAS/MAPK-driven solid tumors, supported by investigator-sponsored trials and combinations with agents such as paclitaxel, pegylated liposomal doxorubicin, letrozole, anastrozole, and cetuximab. Founded in 2010 and headquartered in Needham, Massachusetts, Verastem operates primarily in the United States with a global development strategy through partnerships, employing approximately 78 people under CEO Daniel Paterson. In recent developments, the U.S. FDA approved the avutometinib plus defactinib combination (AVMAPKI FAKZYNJA) as the first therapy for adult patients with KRAS-mutant recurrent LGSOC, with commercialization underway following a planned mid-2025 launch; the company refinanced debt with Oberland Capital, entered a strategic commercialization partnership with IQVIA, completed a $75 million private placement, advanced the GenFleet Therapeutics collaboration with Phase 1/2 initiation of VS-7375 (GFH375) in July 2024 after Chinese IND approval in June 2024, and outlined 2025 priorities including RAMP trials and pipeline expansion.
Company News
Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript
Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III
Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers
Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)
Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect?
Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem (NASDAQ:VSTM) Given Buy Rating at BTIG Research
HC Wainwright Reaffirms “Buy” Rating for Verastem (NASDAQ:VSTM)
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
Head to Head Survey: Verastem (NASDAQ:VSTM) & Sangamo Therapeutics (NASDAQ:SGMO)
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
Verastem (NASDAQ:VSTM) Shares Up 7.1% – Time to Buy?
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright
Verastem, Inc. (NASDAQ:VSTM) Given Consensus Recommendation of “Moderate Buy” by Brokerages